Navigation Links
Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Date:10/30/2010

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load below the lower limit of quantifiable levels in HCV treatment-naive patients. The regimen did not include interferon through the first 28 days of treatment. These data are being presented at the American Association for the Study of Liver Diseases (AASLD) 2010 Liver Meeting in Boston, MA.

(Poster LB-7) New protease-polymerase inhibitor combination resulted in 73-100% rapid virological responses without pegylated interferonIn this randomized open-label trial, 32 treatment-naive genotype-1 HCV patients received BI 207127 in either 400mg or 600mg doses three times a day (TID), BI 201335 120mg once daily (QD) and ribavirin (RBV) (1000/1200mg daily in two doses) for 28 days. All patients had a rapid and sharp decline in HCV viral load during the first two days, followed by a slower second phase decline. In the lower and higher dose groups, 73 and 100% of patients achieved a rapid virological response (i.e. HCV RNA below lower limit of quantification after 4 weeks of treatment). One patient experienced a viral breakthrough (increase by >1 LOG10 from nadir during treatment) and one other experienced a 0.7 LOG10 increase in viral load. Both were in the lower dose group of BI 207127 and were patients with high baseline viral load. On day 29, all patients were switched to treatment with BI 201335 and PegIFN/RBV for an additional 44 weeks per the defined study protocol, and will be followed to evaluate sustained virological response.

"The current standard-of-care, PegIFN/RBV, is challenging for patients with chronic hepatitis C due to significant side effects that impact treatment adherence and has suboptimal response
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 2, 2015 Islamic ... mainstream reporting standard for Corporate Sustainability and Social ... big step in CSR: The Islamic Reporting Initiative (IRI). ... last month, the Islamic Reporting Initiative is rapidly ... The latest members to express support for ...
(Date:6/1/2015)... -- LaunchPad Medical, LLC announced today that it has ... Corporation,s (NYSE: SYK ) bone adhesive technology, ... Under the terms of the agreement, LaunchPad has ... this technology which is covered by four issued ... from multiple pre-clinical animal studies.  LaunchPad will seek ...
(Date:6/1/2015)... WOODBRIDGE, ON , June 1, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... to deliver on its business strategies despite its ...
Breaking Medicine Technology:Call for Partners: Islamic CSR 2LaunchPad Medical Executes Definitive License Agreement with Stryker for Novel Bone Adhesive Technology 2Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
(Date:6/2/2015)... Viejo, CA (PRWEB) June 02, 2015 TranSlice: ... with a new style. TranSlice: Reveal allows Final Cut Pro ... and growing lines to reveal their next screen. , TranSlice ... unique style. Final Cut Pro X users can ... and growing lines. , With every panel orientation and direction ...
(Date:6/2/2015)... Amercanex, the American Cannabis Exchange, ... become Amercanex’s new Chief Technology Officer. Amercanex is ... cultivators, wholesale distributors and retail vendors can buy, ... transparent intra-state market. , Jim Miller is an ... space, helping innovative technology companies deliver on their ...
(Date:6/2/2015)... June 02, 2015 Thermi, formerly ... company has successfully transitioned into its new company ... to the company’s continued rapid worldwide expansion and ... of over 25 Thermi employees, including those of ... teams. , “As one of the fastest growing ...
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... June 02, 2015 Specialty Technical ... compliance and risk solutions , and Radar today ... management effectiveness gap-improvement program. , All organizations need ... on objectives. Organizations not only assess and treat ... to do this (risk managing) thereby embedding these ...
Breaking Medicine News(10 mins):Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4
... , Feb. 16 In these difficult times in ... bringing money and services into the Reno area.   ... Start Learning Disabilities Programs Inc. is providing cutting edge educational and ... The $200,000.00 represents a net investment into the area. ...
... University researchers have developed a hands-free alternative to cell phone ... doing it, make it safer," said Juan Gilbert, professor and ... Computing. He said one problem with banning texting while ... He said it will be difficult for police to can,t ...
... radiological evidence suggest broken leg, malaria and genetic disorder ... King Tut probably wasn,t killed by a vengeful wife ... a broken leg and several inherited disorders that rendered ... new DNA and radiological evidence suggests. , "What ...
... Washington, DC Combining tamoxifen, the world,s most prescribed breast ... feverfew may prevent initial or future resistance to the drug, ... reported online in FASEB Feb. 12, provides ... also tests a novel way to get around it. "A ...
... them with a laser has been shown to be a ... occur in places where a laser light can,t reach? Scientists ... directing gold nanoparticles into the nuclei of cancer cells, they ... them where they lurk. The research appeared as a communication ...
... peer-reviewed international journal of the American Cancer Society, ... in its Jan. 1 edition, demonstrating disparities in ... white women. The HealthCore study reiterates ... populations using government health programs that African-American ...
Cached Medicine News:Health News:Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area 2Health News:King Tut's Demise Gets New Explanation 2Health News:King Tut's Demise Gets New Explanation 3Health News:GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen 2Health News:GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen 3Health News:Using gold nanoparticles to hit cancer where it hurts 2Health News:Cancer publishes study confirming disparity in breast cancer treatment 2
For reconstruction, trauma and chronic stenosis of canalicular system. Medical grade silicone tubing (tapered at one end). Blue polypropylene suture. Box of 3, sterile....
Recommended to insert plug portion of all monocanalicular intubation systems into punctum....
For proper plug sizing....
For proper plug sizing....
Medicine Products: